Journey Medical Corporation announced that the FDA has accepted the Company's New Drug Application (NDA) for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of November 4, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.57 USD | +3.78% | +1.71% | -38.02% |
01/05 | Journey Medical Corporation Appoints Joseph M. Benesch as Chief Financial Officer | CI |
21/03 | Transcript : Journey Medical Corporation, 2023 Earnings Call, Mar 21, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.02% | 68.71M | |
+32.95% | 700B | |
+26.51% | 569B | |
-4.97% | 358B | |
+18.83% | 330B | |
+3.54% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+6.70% | 161B |
- Stock Market
- Equities
- DERM Stock
- News Journey Medical Corporation
- Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea